Patient enrolment has been completed for the PhII EFTISARC-NEO trial of efti in #softtissuesarcoma being conducted by the Maria Sklodowska-Curie National Research Institute of Oncology. 

Further data is expected in 2025.

#immunooncology  #LAG3
ASX:
#softtissuesarcoma
#softtissuesarcoma #immunooncology #LAG3